Nona Biosciences, a global biotechnology company providing a total solution from “Idea to IND” (I to I), announced that BeiGene Ltd. has exercised its exclusive option to acquire global development, manufacturing, and commercialization rights for an antibody-drug conjugate (ADC) from DualityBio, a collaborator of Nona Biosciences.
This ADC was developed under the collaboration agreement established between Nona Biosciences and DualityBio in 2022. Under the terms of the agreement, Nona Biosciences granted DualityBio exclusive rights to certain monoclonal antibodies targeting specific tumours, enabling the development of first-in-class ADC candidates worldwide.
Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing a total solution from “Idea to IND” (I to I), ranging from target validation and antibody discovery through preclinical research.
